Welanclav 457: Purity and Power Against Stubborn Infections

When a common cold turns into something more serious, like a persistent ear infection or a painful case of tonsillitis, your doctor may look for a treatment that is both potent and pure. Welanclav 457 Dry Syrup is a globally trusted antibiotic combination designed to tackle bacterial infections head-on, particularly for children and those who prefer a liquid format.

The Science of “Co-Amoxiclav”

Welanclav 457 contains a powerful duo: Amoxycillin (400 mg) and Potassium Clavulanate (57 mg).

While Amoxycillin does the heavy lifting by destroying the bacterial cell wall, the Clavulanate acts as a “bodyguard.” It stops bacteria from producing enzymes that would otherwise neutralize the antibiotic, making this combination effective even against resistant strains.

Why Quality Matters

Not all syrups are created equal. Welanclav 457 stands out due to its high-tech manufacturing process:

• Robotic Technology: Prepared with a closed-loop operation, ensuring the powder is never exposed to the atmosphere before you open it.

• Enzymatic Synthesis: This method ensures higher purity of the Amoxycillin.

• Moisture Protection: Induction sealing provides maximum stability, so the medicine stays effective throughout its shelf life.

• Delicious Mango Flavor: Designed to make medicine time easier for both parents and children.

Common Indications

Following ICMR guidelines, this combination is often the first-line therapy for:

• Respiratory Issues: Bronchitis, Pharyngitis, and Sinusitis.

• Throat Infections: Tonsillitis.

• Skin & Soft Tissue Infections (SSTI): Infected cuts or rashes.

How to Use

Welanclav 457 comes as a dry powder with Sterile Water for Reconstitution. Simply mix as directed by your pharmacist to create the suspension. Remember, it is vital to complete the full course of antibiotics, even if symptoms improve early!

Disclaimer: Welanclav 457 is a prescription (Rx) medication. Only use this under the direct supervision of a healthcare professional.